About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ATAC - Pharmacokinetics (PK) Sub-Protocol | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 3NCT00784862

ATAC - Pharmacokinetics (PK) Sub-Protocol

To assess the effect of ARIMIDEX on the pharmacokinetics of tamoxifen and the effects of tamoxifen on the pharmacokinetics of ARIMIDEX..

Lead sponsor: AstraZeneca•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

45 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•Eligible for entry into the main ATAC trial 1033IL/0029
•Patients must have been taking ATAC trial medication for at least 3 months (i.e. patients must have reached at least visit 2 of the main ATAC study)
•Patients should be taking their medication in the mornings for at least 3 months
•Patients must be 100% compliant over the preceding fourteen days

Exclusion Criteria

•Excluded from entry into the main ATAC trial (1033IL/0029)
•Patients whose concurrent treatment includes diazepam or drugs which might affect tamoxifen steady state levels or steroid hormone status. These include ketoconazole (antifungal) or related compounds

Related studies

RECRUITINGPhase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

RECRUITINGPhase 1

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

NCT06347068 · Breast Cancer, Relapse, and more

A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

NCT07655934 · Breast Cancer

MRg-NIRS Imaging System Breast Cancer Trial

NCT06400563 · Breast Cancer

RECRUITINGPhase 1/2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 15, 2009Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment9,358

Start dateJun 1998

Last updatedMay 15, 2009

Condition

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 15, 2009Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions